Jazz Pharmaceuticals

Jazz Pharmaceuticals is a biopharmaceutical company based in Ireland. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. The company is also a member of the Pharmaceutical Research and Manufacturers of America. It was founded in 2003.
Jazz Pharmaceuticals stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Jazz Pharmaceuticals balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Jazz Pharmaceuticals cash flows

Report period2019 2020 2021 2022 2023 Q2 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Jazz Pharmaceuticals multipliers

Report period2019 2020 2021 2022 2023 Q2 24 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Jazz Pharmaceuticals profitability

Report period2019 2020 2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Jazz Pharmaceuticals assets
Jazz Pharmaceuticals cash flows

Jazz Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
JAZZ:USJazz Pharmaceuticals PlcCommon share-IE00B4Q5ZN47$109.9
Jazz Pharmaceuticals news
05.05.2022
Jazz Pharmaceuticals' GAAP net income for the 3 months of 2022 was $1.647 million, down 74 times from $121.832 million in the previous year. Revenue increased 33.9% to $813.721 million from $607.581 million a year earlier.
Source: {source} pictogram investor.jazzpharma.com
Pictogram next
25.03.2022
Jazz Pharmaceuticals and GW Pharmaceuticals will build a new manufacturing facility in Kent Science Park, Sittingbourne. The facility will produce two cannabis-based drugs as well as new drugs. Production is scheduled to begin in 2024. The investment will be $100 million.
Source: {source} pictogram investor.jazzpharma.com
Pictogram next
02.03.2022
Jazz Pharmaceuticals' GAAP loss for 2021 was $329.668 million, compared to a profit of $238.616 million in the previous year. Revenue increased 30.9% to $3.094 billion from $2.364 billion a year earlier.
Source: {source} pictogram investor.jazzpharma.com
Pictogram next
10.11.2021
Jazz Pharmaceuticals' GAAP loss for 9M 2021 was $294.317 million, against a profit of $105.202 million in the previous year. Revenue increased 29.4% to $2.198 billion from $1.698 billion a year earlier.
Source: {source} pictogram investor.jazzpharma.com
Pictogram next
All Jazz Pharmaceuticals news
General information
Company nameJazz Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressFIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 4 353-1-634-7800
Mailing addressFIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 4
Websiteinvestor.jazzpharma.com
Information disclosurewww.sec.gov